ENTITY
BeiGene

BeiGene (6160 HK)

328
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
21 Mar 2020 21:00

InnoCare Pharma: Trading Debut, Valuation Scenario Analysis

InnoCare Pharma Ltd (9969 HK) is a pre-revenue biotech company with a focus on research and development, manufacturing and commercialisation of...

Logo
340 Views
Share
13 Mar 2020 14:16

InnoCare (诺诚健华) IPO: Bifurcated Book, Update of Our View

InnoCare launched the book building on March 11th to raise up to USD 288 million to list in Hong Kong. Book building will end on March 16...

Logo
455 Views
Share
11 Mar 2020 16:48

InnoCare Pharma IPO: Valuation Easy to Swallow

InnoCare Pharma Ltd (9969 HK) is a pre-revenue biotech company with a focus on research and development, manufacturing and commercialisation of...

Logo
472 Views
Share
05 Mar 2020 10:35

A Bottom Has Been Established; Possible Retest?

In today’s report we outline  our belief that the combination of extreme oversold conditions and several key sectors/industries holding above major...

Logo
369 Views
Share
11 Feb 2020 00:32

InnoCare Pharma IPO Initiation: Promising Prognosis

InnoCare Pharma Ltd (1576300D CH) is a pre-revenue biotech company with a focus on research and development, manufacturing and commercialisation of...

Logo
390 Views
Share
x